Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a morbid condition for which surgical and ablative
therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 …
therapy are the only options for cure. Nonetheless, over half of patients treated with an R0 …
Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough
GD Dodd, MC Soulen, RA Kane, T Livraghi, WR Lees… - Radiographics, 2000 - pubs.rsna.org
Six existing minimally invasive techniques for the treatment of primary and secondary
malignant hepatic tumors—radio-frequency ablation, microwave ablation, laser ablation …
malignant hepatic tumors—radio-frequency ablation, microwave ablation, laser ablation …
Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective
RTP Poon, ST Fan, FHF Tsang, J Wong - Annals of surgery, 2002 - journals.lww.com
Objective This article reviews the current results of various locoregional therapies for
hepatocellular carcinoma (HCC), with special reference to the implications for surgeons …
hepatocellular carcinoma (HCC), with special reference to the implications for surgeons …
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study
HB El-Serag, AB Siegel, JA Davila, YH Shaib… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: There are several treatment alternatives available for patients
diagnosed with hepatocellular carcinoma (HCC). Yet, neither the extent to which potentially …
diagnosed with hepatocellular carcinoma (HCC). Yet, neither the extent to which potentially …
Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma
BACKGROUND: Local recurrence rates after radiofrequency ablation (RFA) of
hepatocellular carcinoma (HCC) vary from 2% to 36% in the literature. Limited data were …
hepatocellular carcinoma (HCC) vary from 2% to 36% in the literature. Limited data were …
Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis
Background Different approaches to surgical treatment of portal vein tumor thrombosis
(PVTT) have been advocated. This study investigated the outcomes of different surgical …
(PVTT) have been advocated. This study investigated the outcomes of different surgical …
Surgical management of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the second most common cause of death from cancer
worldwide. Standard potentially curative treatments are either resection or transplantation …
worldwide. Standard potentially curative treatments are either resection or transplantation …
Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta‐analysis
Experimental studies suggest that the regenerating liver provides a “fertile field” for the
growth of hepatocellular carcinoma (HCC). However, clinical studies report conflicting …
growth of hepatocellular carcinoma (HCC). However, clinical studies report conflicting …
Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors
Background Complete ablation rates after a single session of radiofrequency ablation (RFA)
of hepatocellular carcinoma (HCC) vary from 48% to 97%. Limited data are available …
of hepatocellular carcinoma (HCC) vary from 48% to 97%. Limited data are available …
Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
CB O'Suilleabhain, RTP Poon, JL Yong… - Journal of British …, 2003 - academic.oup.com
Background Transarterial chemoembolization (TACE) is widely used for unresectable
hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear …
hepatocellular carcinoma (HCC), but the long-term survival benefit remains unclear …